Literature DB >> 21114638

Response to second generation antipsychotics in youth with comorbid bipolar disorder and autism spectrum disorder.

Gagan Joshi1, Joseph Biederman, Janet Wozniak, Robert Doyle, Paul Hammerness, Maribel Galdo, Nora Sullivan, Courtney Williams, Kristin Brethel, K Yvonne Woodworth, Eric Mick.   

Abstract

OBJECTIVE: To assess the impact of comorbid autism spectrum disorders (ASD) on the response to second-generation antipsychotics (SGA) in pediatric bipolar disorder (BPD).
METHODS: Secondary analysis of identically designed 8-week open-label trials of SGA monotherapy (risperidone, olanzapine, quetiapine, ziprasidone, or aripiprazole) in youth with BPD.
RESULTS: Of the 151 BPD subjects 15% (n= 23) met criteria for comorbid ASD. There were no differences in the rate of antimanic response (YMRS change ≥30% or CGI-Improvement ≤2: 65% vs. 69%; P= 0.7) in the presence of comorbid ASD.
CONCLUSION: No difference observed in the rate of antimanic response or tolerability to SGA monotherapy in the presence of ASD comorbidity.
© 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21114638      PMCID: PMC6493433          DOI: 10.1111/j.1755-5949.2010.00219.x

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN: 1755-5930            Impact factor:   5.243


  31 in total

1.  Historical development and present status of the schedule for affective disorders and schizophrenia for school-age children (K-SADS).

Authors:  P J Ambrosini
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2000-01       Impact factor: 8.829

2.  Discriminative validity of a parent version of the Young Mania Rating Scale.

Authors:  Barbara L Gracious; Eric A Youngstrom; Robert L Findling; Joseph R Calabrese
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2002-11       Impact factor: 8.829

3.  Factor structure of the Young Mania Rating Scale for use with youths ages 5 to 17 years.

Authors:  Eric A Youngstrom; Carla Kmett Danielson; Robert L Findling; Barbara L Gracious; Joseph R Calabrese
Journal:  J Clin Child Adolesc Psychol       Date:  2002-12

4.  New subscales for an anchored version of the Brief Psychiatric Rating Scale: construction, reliability, and validity in acute psychiatric admissions.

Authors:  D Lachar; S E Bailley; H M Rhoades; A Espadas; M Aponte; K A Cowan; P Gummattira; C R Kopecky; A Wassef
Journal:  Psychol Assess       Date:  2001-09

5.  Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.

Authors:  Sarah Shea; Atilla Turgay; Alan Carroll; Miklos Schulz; Herbert Orlik; Isabel Smith; Fiona Dunbar
Journal:  Pediatrics       Date:  2004-10-18       Impact factor: 7.124

6.  Risperidone for the treatment of affective symptoms in children with disruptive behavior disorder: a post hoc analysis of data from a 6-week, multicenter, randomized, double-blind, parallel-arm study.

Authors:  Joseph Biederman; Eric Mick; Stephen V Faraone; Janet Wozniak; Thomas Spencer; Gahan Pandina
Journal:  Clin Ther       Date:  2006-05       Impact factor: 3.393

7.  Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children.

Authors:  Joseph Biederman; Eric Mick; Paul Hammerness; Theresa Harpold; Megan Aleardi; Meghan Dougherty; Janet Wozniak
Journal:  Biol Psychiatry       Date:  2005-10-01       Impact factor: 13.382

8.  A double-blind randomized pilot study comparing quetiapine and divalproex for adolescent mania.

Authors:  Melissa P Delbello; Robert A Kowatch; Caleb M Adler; Kevin E Stanford; Jeffrey A Welge; Drew H Barzman; Erik Nelson; Stephen M Strakowski
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2006-03       Impact factor: 8.829

9.  Prevalence of infantile autism in four French regions.

Authors:  E Fombonne; C du Mazaubrun
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1992-08       Impact factor: 4.328

10.  Risperidone in children with autism and serious behavioral problems.

Authors:  James T McCracken; James McGough; Bhavik Shah; Pegeen Cronin; Daniel Hong; Michael G Aman; L Eugene Arnold; Ronald Lindsay; Patricia Nash; Jill Hollway; Christopher J McDougle; David Posey; Naomi Swiezy; Arlene Kohn; Lawrence Scahill; Andres Martin; Kathleen Koenig; Fred Volkmar; Deirdre Carroll; Allison Lancor; Elaine Tierney; Jaswinder Ghuman; Nilda M Gonzalez; Marco Grados; Benedetto Vitiello; Louise Ritz; Mark Davies; James Robinson; Don McMahon
Journal:  N Engl J Med       Date:  2002-08-01       Impact factor: 91.245

View more
  4 in total

1.  Are there lessons to be learned from the prevailing patterns of psychotropic drug use in patients with autism spectrum disorder?

Authors:  G Joshi
Journal:  Acta Psychiatr Scand       Date:  2017-01       Impact factor: 6.392

2.  Comparison of aripiprazole and other atypical antipsychotics for pediatric bipolar disorder: a retrospective chart review of efficacy and tolerability.

Authors:  Jooyoung Oh; Jhin Goo Chang; Seul Bi Lee; Dong-Ho Song; Keun-Ah Cheon
Journal:  Clin Psychopharmacol Neurosci       Date:  2013-08-26       Impact factor: 2.582

3.  Glutamate, Glutamine and GABA Levels in Rat Brain Measured Using MRS, HPLC and NMR Methods in Study of Two Models of Autism.

Authors:  Elzbieta Zieminska; Beata Toczylowska; Dominik Diamandakis; Wojciech Hilgier; Robert Kuba Filipkowski; Rafal Polowy; Jaroslaw Orzel; Michal Gorka; Jerzy Wieslaw Lazarewicz
Journal:  Front Mol Neurosci       Date:  2018-11-16       Impact factor: 5.639

Review 4.  Aripiprazole for treating irritability in children & adolescents with autism: A systematic review.

Authors:  Ahmad Ghanizadeh; Sylvie Tordjman; Nematollah Jaafari
Journal:  Indian J Med Res       Date:  2015-09       Impact factor: 2.375

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.